GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jiang Xi Sanxin Medtec Co Ltd (SZSE:300453) » Definitions » EBIT

Jiang Xinxin Medtec Co (SZSE:300453) EBIT : ¥279 Mil (TTM As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Jiang Xinxin Medtec Co EBIT?

Jiang Xinxin Medtec Co's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2024 was ¥70 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was ¥279 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Jiang Xinxin Medtec Co's annualized ROC % for the quarter that ended in Dec. 2024 was 19.71%. Jiang Xinxin Medtec Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 26.03%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Jiang Xinxin Medtec Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 6.91%.


Jiang Xinxin Medtec Co EBIT Historical Data

The historical data trend for Jiang Xinxin Medtec Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiang Xinxin Medtec Co EBIT Chart

Jiang Xinxin Medtec Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 155.11 197.45 228.56 257.29 279.18

Jiang Xinxin Medtec Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 81.64 65.98 67.01 76.09 70.09

Competitive Comparison of Jiang Xinxin Medtec Co's EBIT

For the Medical Instruments & Supplies subindustry, Jiang Xinxin Medtec Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiang Xinxin Medtec Co's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Jiang Xinxin Medtec Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Jiang Xinxin Medtec Co's EV-to-EBIT falls into.


;
;

Jiang Xinxin Medtec Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥279 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jiang Xinxin Medtec Co  (SZSE:300453) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Jiang Xinxin Medtec Co's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=332.432 * ( 1 - 8.04% )/( (1566.835 + 1535.336)/ 2 )
=305.7044672/1551.0855
=19.71 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2158.083 - 416.483 - ( 404.123 - max(0, 560.385 - 735.15+404.123))
=1566.835

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2222.71 - 441.015 - ( 468.328 - max(0, 577.596 - 823.955+468.328))
=1535.336

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Jiang Xinxin Medtec Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=280.36/( ( (1066.129 + max(-163.267, 0)) + (1088.251 + max(-150.321, 0)) )/ 2 )
=280.36/( ( 1066.129 + 1088.251 )/ 2 )
=280.36/1077.19
=26.03 %

where Working Capital is:

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(94.25 + 205.486 + 17.128) - (416.483 + 0 + 63.648)
=-163.267

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(83.257 + 195.674 + 68.782) - (441.015 + 0 + 57.019)
=-150.321

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Jiang Xinxin Medtec Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2024 )
=279.176/4038.520
=6.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jiang Xinxin Medtec Co EBIT Related Terms

Thank you for viewing the detailed overview of Jiang Xinxin Medtec Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Jiang Xinxin Medtec Co Business Description

Traded in Other Exchanges
N/A
Address
No. 999, Fushan Avenue, Xiaolan Economic Development Zone, Nanchang County, Jiangxi Province, Nanchang, CHN, 330200
Jiang Xi Sanxin Medtec Co Ltd is engaged in researching and developing, manufacturing and marketing of medical devices. Its products include four series: blood purification, indwelling catheters, injections, infusion and blood transfusion. Blood purification products are used in clinical dialysis treatment for uremic patients. Indwelling catheter products represented by venous indwelling needles, positive pressure indwelling needles, central venous catheters. Injectable products mainly include self-destructing syringes, retracting self-destructing syringes, conjoined syringes.
Executives
Zhang Lin Supervisors
Le Zhen Rong Executives
Mao Zhi Ping Directors, executives
Yu Zhen Zhu Supervisors
Peng Yi Xing Director
Liu Ming Securities Affairs Representative
Wan Xiao Ping Director
Wang Qin Hua Supervisors
Xiong Yan Supervisors

Jiang Xinxin Medtec Co Headlines

No Headlines